Global eosinophilic esophagitis treatment market is growing at a CAGR of 6.4% during the forecast period (2024-2031). The increasing awareness programs for eosinophil-associated disorders drive market growth. In addition, the growing preference for personalized medicine and point-of-care testing along with the increasing development of a potential drug are contributing significantly towards the market growth. Furthermore, the rising technological advancements and modernization of the healthcare sector are presenting novel opportunities for the market, particularly in emerging regions. However, the market growth is challenged by the expensive treatment procedures and lack of awareness.
The global eosinophilic esophagitis treatment market is segmented by product (budesonide oral suspension, fluticasone odt, mepolizumab, reslizumab, benralizumab, and others), by diagnosis (upper endoscopy, esophagus biopsy, and blood tests), by treatment (dietary therapy, medication, and dilation), and, by geographies (North America, Europe, Asia-Pacific, and Rest of the World).
Market Dynamics
- The budesonide oral suspension segment held a prominent market share in 2023, owing to its capability to decrease the peak eosinophil counts in patients with eosinophilic esophagitis.
- Asia-Pacific region is expected to witness significant growth during the forecast period, owing to the improving healthcare infrastructure in the region and the increasing health awareness among people. Additionally, technological advancement in economies such as South Korea, China, and India is driving regional market growth. Furthermore, the increasing medical tourism is also contributing to the regional market growth.
- In addition, North America is anticipated to dominate the global eosinophilic esophagitis treatment market, attributed to the presence of advanced healthcare facilities and major players, and the increasing cases of surgical procedures.
The major players in the global eosinophilic esophagitis treatment market include AstraZeneca, Bristol-Myers Squibb, Novartis AG, Regeneron Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd. among others. The market players are contributing significantly to the market growth, by the adoption of various business strategies, such as collaborations, mergers and acquisitions, product portfolio diversification, and more.
Recent Developments
- In September 2024, Dupixent was recommended for EU approval by the CHMP to treat children younger than 1 year, suffering from eosinophilic esophagitis. The recommendation is based on the results of the phase 3 study, depicting higher histological remission from the drug in children.
- In February 2024, Takeda Pharmaceutical Company Ltd. announced the US Food and Drug Administration (FDA) approval of EOHILIA (budesonide oral suspension). EOHILIA is an oral therapy for people 11 years and older with eosinophilic esophagitis (EoE). It will be available in 2 mg/10 mL single-dose stick packs.
- In January 2024, the FDA approved Dupixent® for children aged 1 year and older suffering from eosinophilic esophagitis (EoE).
- In January 2024, Revolo Biotherapeutics announced that the US Food and Drug Administration (FDA) approved Orphan Drug Designation (ODD) to ‘1104. The peptide is being developed for treating eosinophilic esophagitis (EoE).